Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Adebrelimab in Advanced Triple-Negative Breast Carcinoma: NCT06771609 Clinical Landscape Report 2026
15 October 2026
NCT06771609 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
BC008-1A in Glioblastoma Multiforme: NCT06773481 Clinical Landscape Report 2026
15 October 2026
NCT06773481 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Azacitidine in Diffuse Large B-Cell Lymphoma: NCT06778902 Clinical Landscape Report 2026
15 October 2026
NCT06778902 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LNCB-74 in Ovarian Cancer: NCT06774963 Clinical Landscape Report 2026
15 October 2026
NCT06774963 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lutetium (177 Lu) Vipivotide Tetraxetan in Metastatic Clear Cell Renal Cell Carcinoma: NCT06783348 Clinical Landscape Report 2026
15 October 2026
NCT06783348 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
B7H3-IRDye800CW in Osteosarcoma: NCT06778603 Clinical Landscape Report 2026
15 October 2026
NCT06778603 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06780592 Clinical Landscape Report 2026
15 October 2026
NCT06780592 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Odronextamab in Primary mediastinal large B-cell lymphoma recurrent: NCT06784726 Clinical Landscape Report 2026
15 October 2026
NCT06784726 clinical landscape for Primary mediastinal large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and dev…
9 min read
Capecitabine in Triple Negative Breast Cancer: NCT06787339 Clinical Landscape Report 2026
15 October 2026
NCT06787339 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Uveal Melanoma: NCT06784648 Clinical Landscape Report 2026
15 October 2026
NCT06784648 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TIL therapy(Herlev Hospital) in Malignant melanoma, metastatic: NCT06783270 Clinical Landscape Report 2026
15 October 2026
NCT06783270 clinical landscape for Malignant melanoma, metastatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19/BCMA CAR Tcells therapy (Yake Biotechnology) in Lupus Nephritis: NCT06785519 Clinical Landscape Report 2026
15 October 2026
NCT06785519 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.